Satoh F, Umemura S, Osamura R Y
Department of Pathology, Tokai University School of Medicine, Isehara, Japan.
Breast Cancer. 2000 Jan;7(1):49-55. doi: 10.1007/BF02967188.
Gross cystic disease fluid protein (GCDFP)-15, a major constituent protein in breast cysts, is known to be a marker of breast cancer, while the diagnostic value of GCDFP-24, a protein with a molecular weight of 24,000 daltons, has not been determined. The aim of this study was to elucidate the usefulness of GCDFP-24 for the differential diagnosis of breast cancer in combination with GCDFP-15 and to characterize the histologic features of GCDFP-24-positive breast cancer.
A total of 326 samples including non-neoplastic tissue and benign and malignant tumors from several anatomic sites were examined using commercially available monoclonal antibodies against GCDFP-15 and GCDFP-24.
In non-mammary tissue, GCDFP-15 was detected in skin, salivary gland, bronchial gland, prostate and seminal vesicle, and GCDFP-24 was detected in apocrine glands and peripheral nerve. Thirty-seven (44.6%) and 22 (26.5%) samples of 83 breast cancers were positive for GCDFP-15 and -24, respectively. Combined assays of GCDFP-15 and -24 raised the positive rate to 50.6%. The markers were not detected in tumors originating from gastrointestinal tract, bronchopulmonary structures or the genitourinary system. Breast cancers positive for both GCDFP-15 and GCDFP-24 were of lower histologic grade according to Bloom & Richardson's scoring system (p < 0.05).
Immunohistochemical analysis of GCDFP-24 in combination with GCDFP-15 expression was useful for definitive diagnosis of breast cancers, and the expression of these markers correlated with low grade breast cancer.
乳腺囊肿中的主要成分蛋白——大囊性病液蛋白(GCDFP)-15是已知的乳腺癌标志物,而分子量为24000道尔顿的蛋白GCDFP-24的诊断价值尚未确定。本研究的目的是阐明GCDFP-24联合GCDFP-15对乳腺癌鉴别诊断的有用性,并描述GCDFP-24阳性乳腺癌的组织学特征。
使用市售的抗GCDFP-15和GCDFP-24单克隆抗体检测了包括非肿瘤组织以及来自多个解剖部位的良性和恶性肿瘤在内的共326个样本。
在非乳腺组织中,GCDFP-15在皮肤、唾液腺、支气管腺、前列腺和精囊腺中被检测到,GCDFP-24在顶泌汗腺和周围神经中被检测到。83例乳腺癌样本中,分别有37例(44.6%)和22例(26.5%)GCDFP-15和GCDFP-24呈阳性。GCDFP-15和GCDFP-24联合检测使阳性率提高到50.6%。在源自胃肠道、支气管肺结构或泌尿生殖系统的肿瘤中未检测到这些标志物。根据布鲁姆和理查森评分系统,GCDFP-15和GCDFP-24均阳性的乳腺癌组织学分级较低(p<0.05)。
GCDFP-24与GCDFP-15表达联合的免疫组化分析对乳腺癌的明确诊断有用,且这些标志物的表达与低级别乳腺癌相关。